Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Rosenfeld, Nitzan"'
Autor:
Weaver, Jamie MJ, Ross-Innes, Caryn S, Shannon, Nicholas, Lynch, Andy G, Forshew, Tim, Barbera, Mariagnese, Murtaza, Muhammed, Ong, Chin-Ann J, Lao-Sirieix, Pierre, Dunning, Mark J, Smith, Laura, Smith, Mike L, Anderson, Charlotte L, Carvalho, Benilton, O'Donovan, Maria, Underwood, Timothy J, May, Andrew P, Grehan, Nicola, Hardwick, Richard, Davies, Jim, Oloumi, Arusha, Aparicio, Sam, Caldas, Carlos, Eldridge, Matthew D, Edwards, Paul AW, Rosenfeld, Nitzan, Tavaré, Simon, Fitzgerald, Rebecca C, OCCAMS Consortium
Publikováno v:
Nature genetics
Cancer genome sequencing studies have identified numerous driver genes, but the relative timing of mutations in carcinogenesis remains unclear. The gradual progression from premalignant Barrett's esophagus to esophageal adenocarcinoma (EAC) provides
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92e3f5463bad34aca63cca5b88b4991a
Autor:
Remon, J, Caramella, C, Jovelet, C, Lacroix, L, Lawson, Andrew, Smalley, S, Howarth, K, Gale, Davina, Green, E, Plagnol, V, Rosenfeld, Nitzan, Planchard, D, Bluthgen, MV, Gazzah, A, Pannet, C, Nicotra, C, Auclin, E, Soria, JC, Besse, B
Background: Approximately 50% of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs) will acquire resistance by the T790M mutation. Osimertinib is the standard
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::218c824277d1fafe61b827249ca91669
Autor:
Schwarz, Roland F, Ng, Charlotte KY, Cooke, Susanna L, Newman, Scott, Temple, Jillian, Piskorz, Anna M, Gale, Davina, Sayal, Karen, Murtaza, Muhammed, Baldwin, Peter J, Rosenfeld, Nitzan, Earl, Helena M, Sala, Evis, Jimenez-Linan, Mercedes, Parkinson, Christine A, Markowetz, Florian, Brenton, James D
Publikováno v:
PLoS Medicine
PLoS Medicine, Vol 12, Iss 2, p e1001789 (2015)
PLoS Medicine, Vol 12, Iss 2, p e1001789 (2015)
Background The major clinical challenge in the treatment of high-grade serous ovarian cancer (HGSOC) is the development of progressive resistance to platinum-based chemotherapy. The objective of this study was to determine whether intra-tumour geneti
Autor:
Smith, Christopher G, Moser, Tina, Mouliere, Florent, Field-Rayner, Johanna, Eldridge, Matthew, Riediger, Anja L, Chandrananda, Dineika, Heider, Katrin, Wan, Jonathan CM, Warren, Anne Y, Morris, James, Hudecova, Irena, Cooper, Wendy N, Mitchell, Thomas J, Gale, Davina, Ruiz-Valdepenas, Andrea, Klatte, Tobias, Ursprung, Stephan, Sala, Evis, Riddick, Antony CP, Aho, Tevita F, Armitage, James N, Perakis, Samantha, Pichler, Martin, Seles, Maximilian, Wcislo, Gabriel, Welsh, Sarah J, Matakidou, Athena, Eisen, Tim, Massie, Charles E, Rosenfeld, Nitzan, Heitzer, Ellen, Stewart, Grant D
BACKGROUND: Cell-free tumor-derived DNA (ctDNA) allows non-invasive monitoring of cancers, but its utility in renal cell cancer (RCC) has not been established. METHODS: Here, a combination of untargeted and targeted sequencing methods, applied to two
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e859b0bf44a7f73ff06d090b0e230bb0
Autor:
Christopher Smith, Katrin Heider, Tevita Aho, Maximilian Seles, Grant D. Stewart, Evis Sala, Johanna Field-Rayner, Irena Hudecova, Charles E. Massie, Anja L. Riediger, Tobias Klatte, Jonathan C. M. Wan, Ellen Heitzer, Florent Mouliere, Wendy N. Cooper, Antony C. P. Riddick, Matthew D. Eldridge, Dineika Chandrananda, James Morris, Tina Moser, Martin Pichler, Davina Gale, Nitzan Rosenfeld, Gabriel Wcislo, Anne Y. Warren, Samantha Perakis, Sarah J. Welsh, Tim Eisen, James N. Armitage, Stephan Ursprung, Thomas J. Mitchell, Andrea Ruiz-Valdepeñas, Athena Matakidou
Publikováno v:
Genome Medicine, Vol 12, Iss 1, Pp 1-17 (2020)
Genome Medicine, 12(1):23. BioMed Central
Smith, C G, Moser, T, Mouliere, F, Field-Rayner, J, Eldridge, M, Riediger, A L, Chandrananda, D, Heider, K, Wan, J C M, Warren, A Y, Morris, J, Hudecova, I, Cooper, W N, Mitchell, T J, Gale, D, Ruiz-Valdepenas, A, Klatte, T, Ursprung, S, Sala, E, Riddick, A C P, Aho, T F, Armitage, J N, Perakis, S, Pichler, M, Seles, M, Wcislo, G, Welsh, S J, Matakidou, A, Eisen, T, Massie, C E, Rosenfeld, N, Heitzer, E & Stewart, G D 2020, ' Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors ', Genome Medicine, vol. 12, no. 1, 23, pp. 23 . https://doi.org/10.1186/s13073-020-00723-8
Genome Medicine
Genome Medicine, 12(1):23. BioMed Central
Smith, C G, Moser, T, Mouliere, F, Field-Rayner, J, Eldridge, M, Riediger, A L, Chandrananda, D, Heider, K, Wan, J C M, Warren, A Y, Morris, J, Hudecova, I, Cooper, W N, Mitchell, T J, Gale, D, Ruiz-Valdepenas, A, Klatte, T, Ursprung, S, Sala, E, Riddick, A C P, Aho, T F, Armitage, J N, Perakis, S, Pichler, M, Seles, M, Wcislo, G, Welsh, S J, Matakidou, A, Eisen, T, Massie, C E, Rosenfeld, N, Heitzer, E & Stewart, G D 2020, ' Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors ', Genome Medicine, vol. 12, no. 1, 23, pp. 23 . https://doi.org/10.1186/s13073-020-00723-8
Genome Medicine
BackgroundCell-free tumor-derived DNA (ctDNA) allows non-invasive monitoring of cancers, but its utility in renal cell cancer (RCC) has not been established.MethodsHere, a combination of untargeted and targeted sequencing methods, applied to two inde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cbab7bf4108a7426b98121afa51b566
https://www.repository.cam.ac.uk/handle/1810/303983
https://www.repository.cam.ac.uk/handle/1810/303983
Autor:
Keval M. Patel, Charles E. Massie, Vincent J. Gnanapragasam, Tim Forshew, K. E. van der Vos, Florent Mouliere, Francesco Marass, Dana W.Y. Tsui, Dineika Chandrananda, M.S. van der Heijden, D. Van Den Broek, James Morris, Nitzan Rosenfeld, David E. Neal, B.W.G. Van Rhijn, Christopher Smith
Publikováno v:
Scientific Reports
Scientific Reports, 7(1):5554. Nature Publishing Group
Patel, K M, Van Der Vos, K E, Smith, C G, Mouliere, F, Tsui, D, Morris, J A, Chandrananda, D, Marass, F, Van Den Broek, D, Neal, D E, Gnanapragasam, V J, Forshew, T, Van Rhijn, B W, Massie, C E, Rosenfeld, N & Van Der Heijden, M S 2017, ' Association of Plasma and Urinary Mutant DNA with Clinical Outcomes in Muscle Invasive Bladder Cancer ', Scientific Reports, vol. 7, no. 1, 5554 . https://doi.org/10.1038/s41598-017-05623-3
Scientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
Scientific Reports, 7(1):5554. Nature Publishing Group
Patel, K M, Van Der Vos, K E, Smith, C G, Mouliere, F, Tsui, D, Morris, J A, Chandrananda, D, Marass, F, Van Den Broek, D, Neal, D E, Gnanapragasam, V J, Forshew, T, Van Rhijn, B W, Massie, C E, Rosenfeld, N & Van Der Heijden, M S 2017, ' Association of Plasma and Urinary Mutant DNA with Clinical Outcomes in Muscle Invasive Bladder Cancer ', Scientific Reports, vol. 7, no. 1, 5554 . https://doi.org/10.1038/s41598-017-05623-3
Scientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
Muscle Invasive Bladder Cancer (MIBC) has a poor prognosis. Whilst patients can achieve a 6% improvement in overall survival with Neo-Adjuvant Chemotherapy (NAC), many do not respond. Body fluid mutant DNA (mutDNA) may allow non-invasive identificati
Autor:
Parkinson, CA, Gale, D, Piskorz, AM, Biggs, H, Hodgkin, C, Addley, H, Freeman, S, Moyle, P, Sala, E, Sayal, K, Hosking, K, Gounaris, I, Jimenez-Linan, M, Earl, HM, Qian, W, Rosenfeld, N, Brenton, JD
$\textbf{Background:}$ Circulating tumour DNA (ctDNA) carrying tumour-specific sequence alterations may provide a minimally invasive means to dynamically assess tumour burden and response to treatment in cancer patients. Somatic $\textit{TP53}$ mutat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afacd17cc1d6d37f3a363f790600922b
Autor:
Marek Cmero, Niall M. Corcoran, Dana W.Y. Tsui, Anthony J. Costello, Peter Van Loo, Vincent Gnanapragasam, Sebastian Lunke, Christopher M. Hovens, Pramit M. Phal, Haroon Naeem, Keval M. Patel, Ludmil B. Alexandrov, Matthew K.H. Hong, Izhak Haviv, Geoff Macintyre, David C. Wedge, Xiaowen Chin, Anne Y. Warren, Andrew Ryan, Clare Sloggett, Andrew Lonie, Nikhil Sapre, John Pedersen, Francesco Marass, Stefano Mangiola, Nitzan Rosenfeld, David E. Neal, Natalie Kurganovs, Michael Kerger
Publikováno v:
Nature Communications
Tumour heterogeneity in primary prostate cancer is a well-established phenomenon. However, how the subclonal diversity of tumours changes during metastasis and progression to lethality is poorly understood. Here we reveal the precise direction of met